Exelixis vs Neurocrine Biosciences
Exelixis (EXEL), health care, and Neurocrine Biosciences (NBIX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Exelixis and Neurocrine Biosciences are valued at about the same: $16.7B and $16.8B. Exelixis trades at 20.5 times earnings and Neurocrine Biosciences at 24.6; operating margins in their latest fiscal years were 37.6% and 21.6%. Over the past year Exelixis's share price has moved +57.3% and Neurocrine Biosciences's +19.2%.
Key facts
- Exelixis market value
- $16.7B
- Neurocrine Biosciences market value
- $16.8B
- Exelixis P/E
- 20.5
- Neurocrine Biosciences P/E
- 24.6
- Exelixis revenue
- $2.3BFY to 2026-01-02
- Neurocrine Biosciences revenue
- $2.9BFY to 2025-12-31
- Superinvestors holding both
- 2
Market values as of .
| Measure | Exelixis | Neurocrine Biosciences |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2026-01-02 | 2025-12-31 |
| Size | ||
| Market cap | $16.7Blower | $16.8Bhigher |
| Revenue | $2.3Blower | $2.9Bhigher |
| Earnings | $782.6Mhigher | $478.6Mlower |
| Employees | 1,077lower | 2,500higher |
| Total assets | $2.8Blower | $4.6Bhigher |
| Valuation | ||
| P/E | 20.5lower | 24.6higher |
| P/S | 7.2higher | 5.9lower |
| P/B | 9.1higher | 4.3lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 37.6%higher | 21.6%lower |
| Balance sheet | ||
| Net assets | $2.2Blower | $3.3Bhigher |
| Total liabilities | $683.1Mlower | $1.4Bhigher |
| Total debt | — | — |
| Cash on hand | $482.5Mlower | $713Mhigher |
| Price change | ||
| Today | +2.09%higher | +0.37%lower |
| 1 year | +57.3%higher | +19.2%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (2)
- Jim Simons (1938–2024)1.0% / 0.4%
- Cliff Asness0.2% / 0.2%
Exelixis only (3)
Neurocrine Biosciences only (3)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Exelixis / Neurocrine Biosciences). Who owns EXEL · Who owns NBIX
More on Exelixis
Further comparisons
Exelixis against its closest peers
Neurocrine Biosciences against its closest peers
Learn
Questions and answers
Which is bigger, Exelixis or Neurocrine Biosciences?
By market value, Neurocrine Biosciences is the larger: $16.8B against $16.7B for Exelixis. By revenue in its latest fiscal year, Neurocrine Biosciences is the larger: $2.9B against $2.3B for Exelixis.
Which has the higher P/E ratio?
Neurocrine Biosciences: 24.6, against 20.5 for Exelixis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Exelixis: 37.6%, against 21.6% for Neurocrine Biosciences. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Exelixis and Neurocrine Biosciences?
In their latest 13F filings, Jim Simons (1938–2024) and Cliff Asness hold both.
Cite this page
Funkfolio, “Exelixis vs Neurocrine Biosciences”, data as of 18 November 2026. https://funkfolio.com/compare/exel-vs-nbix
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.